|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Sequence variation at the rice blast resistance gene Pi-km locus: Implications for the develop- ment of allele specific markers 显示文摘 | Stefano Costanzo Jia Yu-lin | 2010 | Plant Science2010，178，： | 1 |
| 2 | Sequence variation at the rice blast resistance gene Pi-kmlocus:Implications for the development of allele specific markers显示文摘 | Stefano Costanzo Yulin Jia | 2010 | Plant Science2010，178，： | 1 |
| 3 | Sequence variation at the rice blast re- sistance gene P/-k locus:Implications for the development of allele specific markers显示文摘 | Stefano Costanzo Yulin Jia | 2010 | Plant Science2010，178，： | 1 |
| 4 | Refining sorafenib therapy: lessons from clinical practice显示文摘 | Luigi Bolondi Antonio Craxi Franco Trevisani Bruno Daniele Giovan Giuseppe Di Costanzo Stefano Fagiuoli Calogero Cammà Paolo Bruzzi Romano Danesi Federico Spandonaro Corrado Boni Armando Santoro Massimo Colombo | 2015 | Future Oncol2015，，3： | 1 |
| 5 | Evolutionary Dynamics of the Genomic Region Around the Blast Resistance Gene Pi-ta in AA Genome Oryza Species显示文摘 | Lee Seonghee Costanzo Stefano Jia Yulin Olsen Kenneth M Caicedo Ana L | 2009 | Genetics2009，，4： | 1 |
| 6 | Development of PCR-Based Markers Linked to Quantitative Resistance to Late Blight in a Diploid Hybrid Potato Population of Solanum phureja x S. stenotomum显示文摘 | W. M. D. K. Wickramasinghe Xinshun S. Qu Stefano Costanzo Kathleen G. Haynes Barbara J. Christ | | 0，，： | 1 |
| 7 | Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to α-interferon therapy in chronic HCV hepatitis patients显示文摘 | Marco Artini Clara Natoli Nicola Tinari Antonio Costanzo Rossana Marinelli Clara Balsano Patrizia Porcari Domenico Angelucci Maurizia D’Egidio Massimo Levrero Stefano Iacobelli | 1996 | Journal of Hepatology1996，，2： | 1 |
| 8 | Current progress on genetic interactions of rice with rice blast and sheath blight fungi显示文摘 | Yulin Jia Guangjie Liu Stefano Costanzo Seonghee Lee Yuntao Dai | 2009 | Frontiers of Agriculture in China2009，，3： | 1 |
| 9 | A regulatory feedback loop involving p63 and IRF6 links the pathogenesis of 2 genetically different human ectodermal dysplasias显示文摘 | Moretti Francesca Marinari Barbara Iacono Nadia Lo Botti Elisabetta Giunta Alessandro Spallone Giulia Garaffo Giulia Vernersson-Lindahl Emma Merlo Giorgio Mills Alea A Ballarò Costanza Alemà Stefano Chimenti Sergio Guerrini Luisa Costanzo A | 2010 | Journal of Clinical Investigation2010，，5： | 1 |
| 10 | Evolutionary Dynamics of the Genomic Region Around the Blast Resistance Gene Pita in AA Genome Oryza Species显示文摘 | Seonghee Lee Stefano Costanzo Yulin Jia | 2009 | Genetics2009，183，： | 1 |
| 11 | Sequence variation at the rice blast resistance gene Pi-km locus:Implications for the development of allele specific markers显示文摘 | Stefano Costanzo Yulin Jia | 2010 | Plant Science2010，178，： | 1 |
| 12 | Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcino- ma显示文摘 | Di Costanzo GG De Stefano G Tortora R | 2015 | Future Oncol2015，11，6： | 1 |
| 13 | Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial显示文摘 | Stefano Cascinu Rossana Berardi Roberto Labianca Salvatore Siena Alfredo Falcone Enrico Aitini Sandro Barni Francesco Di Costanzo Elisa Dapretto Giuseppe Tonini Chiara Pierantoni Salvatore Artale Silvia Rota Irene Floriani Mario Scartozzi Alberto Zaniboni | 2008 | Lancet Oncology2008，，1： | 1 |
| 14 | Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib显示文摘AIM:To investigate in greater detail the efficacy and safety of sorafenib for the treatment of hepatocellular carcinoma(HCC)in patients with established cirrhosis.METHODS:From October 2009 to July 2012 patients with an established diagnosis of cirrhosis and HCC treated with sorafenib were consecutively enrolled.According to the Barcelona Clinic Liver Cancer(BCLC)classification,patients were in the advanced stage(BCLC-C)or in the intermediate stage(BCLC-B)but unfit or unresponsive to other therapeutic strategies.Treatment was evaluated performing a 4-phase computed tomography or magnetic resonance imaging scan every 2-3 mo,and analyzed according to the modified Response Evaluation Criteria in Solid Tumors.Sorafenib was administered at 800 mg/d,until radiological progression or occurrence of unacceptable adverse events(AEs).Univariate and multivariate analyses identified predictors of 16-wk clinical benefit and overall survival.RESULTS:Forty-four patients were enrolled,15 had intermediate HCC and 14 a Child-Pugh score of B7.AEs caused treatment interruption in 19 patients(43%),and median treatment duration was shorter in this subset(5 wk vs 19 wk,P<0.001)and in the BCLC-C subgroup(13 wk vs 40 wk,P=0.015).No significant differences in the reason for treatment interruption or in treatment duration were found comparing patients in Child-Pugh class A vs B or in patients older or younger than 70 years.After 16 wk of treatment,18 patients(41%)had stable disease or partial response.Patients with viral infection or BCLC-C were at higher risk of disease progression.ECOG,extrahepatic spread,macrovascular invasion,alpha-fetoprotein or alkaline phosphatase levels at admission were independent predictors of overall survival.CONCLUSION:In patients with cirrhosis and HCC treated with sorafenib,AEs are a common cause of early treatment withdrawal.Vascular invasion and extrahepatic spread condition early response to treatment and survival.Baseline biochemical parameters may be helpful to identify patients at higher risk of shorter overall survival. | Andrea L Inghilesi Donatella Gallori Lorenzo Antonuzzo Paolo Forte Daniela Tomcikova Umberto Arena Stefano Colagrande Silvia Pradella Bernardo Fani Elena Gianni Luca Boni Giacomo Laffi Francesco Di Costanzo Fabio Marra | 2014 | World Journal of Gastroenterology2014，20，3： | 1 |
| 15 | COVID-19: Considerations about immune suppression and biologicals at the time of SARS-CoV-2 pandemic显示文摘The extent of the profound immunological and nonimmunological responses linked to severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection is currently being investigated worldwide due to the large burden associated with death due to SARS-CoV-2 and the short-term consequences of coronavirus disease 2019(COVID-19).It has been hypothesized that patients on immunosuppressive treatments,including biologics,may have an augmented risk of being infected by SARS-CoV-2;however,there are currently no definitive data about biological drugs and COVID-19 in immune-mediated inflammatory diseases.Current epidemiological models developed to understand how long the COVID-19 epidemic may last are not conclusive and range from sustained epidemics to complete elimination.Nevertheless,even in the best-case scenario of apparent elimination,there is concordance about a possible contagion resurgence as late as 2024.Therefore,knowledge of the impact of SARS-CoV-2 on immunemediated diseases and among patients treated with biologicals,together with the results of novel and promising COVID-19 treatment strategies targeting the virus and the host immune response(or both),will help us to best manage our patients during this pandemic over the next few years. | Giulia Costanzo William Cordeddu Luchino Chessa Stefano Del Giacco Davide Firinu | 2021 | World Journal of Clinical Cases2021，9，20： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员